Shares of Moderna, Inc. (MRNA) soared 5.01% during intraday trading on Thursday, driven by the company's announcement of a new clinical trial for an Ebola vaccine and optimism ahead of its upcoming earnings report.
The biotech firm disclosed the launch of a Phase 1 study for its mRNA-1469 vaccine candidate, which aims to prevent Ebola virus infection. This move to expand its mRNA pipeline beyond respiratory diseases signals potential new revenue streams and reinforces Moderna's platform versatility, boosting investor confidence.
Additionally, traders are positioning ahead of Moderna's earnings release scheduled for Friday, with some market sentiment leaning toward a positive surprise, adding further upward momentum to the stock.